Company Analysis Yili Chuannig Biotechnology Co., Ltd.
1. Summary
Advantages
- Price (8.77 Β₯) is less than fair price (33.82 Β₯)
- The stock's return over the last year (21.55%) is higher than the sector average (-36.11%).
Disadvantages
- Dividends (1.04%) are below the sector average (1.83%).
- The company's current efficiency (ROE=8.71%) is lower than the sector average (ROE=11.95%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Yili Chuannig Biotechnology Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.8% | -4.6% | -1.6% |
| 90 days | -20% | -16% | -14.5% |
| 1 year | 21.6% | -36.1% | 18.7% |
301301 vs Sector: Yili Chuannig Biotechnology Co., Ltd. has outperformed the "Healthcare" sector by 57.66% over the past year.
301301 vs Market: Yili Chuannig Biotechnology Co., Ltd. has outperformed the market by 2.84% over the past year.
Stable price: 301301 is not significantly more volatile than the rest of the market on "Shenzhen Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 301301 with weekly volatility of 0.4144% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (8.77 Β₯) is lower than the fair price (33.82 Β₯).
Price significantly below the fair price: The current price (8.77 Β₯) is 285.6% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (36.54) is lower than that of the sector as a whole (69.4).
P/E vs Market: The company's P/E (36.54) is lower than that of the market as a whole (63.57).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.06) is lower than that of the sector as a whole (3.96).
P/BV vs Market: The company's P/BV (3.06) is lower than that of the market as a whole (3.79).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.3) is lower than that of the sector as a whole (6.51).
P/S vs Market: The company's P/S indicator (4.3) is lower than that of the market as a whole (5.87).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (30.12) is higher than that of the sector as a whole (11.85).
EV/Ebitda vs Market: The company's EV/Ebitda (30.12) is higher than that of the market as a whole (25.54).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (8.71%) is lower than that of the sector as a whole (11.95%).
ROE vs Market: The company's ROE (8.71%) is lower than that of the market as a whole (9.38%).
5.5. ROA
ROA vs Sector: The company's ROA (4.94%) is lower than that of the sector as a whole (5.4%).
ROA vs Market: The company's ROA (4.94%) is higher than that of the market as a whole (3.95%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.04% is below the average for the sector '1.83%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.04% has been steadily paid over the past 7 years, DSI=0.75.
Weak dividend growth: The company's dividend yield 1.04% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
